Structured Guidance for Care Delivery May Result in Better Counselling for Patients With Breast Cancer

Article

Nurse Navigator Janeen Bazan, RN, OCN, BSN, talks about the 4R Care Sequence® and its impact on the care of patients with breast cancer at the 2021 Oncology Nursing Society Annual Congress.

According to a poster presentation at the recent 2021 Oncology Nursing Society (ONS) Annual Congress, breast cancer care may benefit from guidance in a new care delivery model.

The 4R Care Sequence® is a one-page, multimodality, personalized care project plan that is used by multidisciplinary teams to plan and deliver care. The 4 Rs in the title represent the right information, care, patient, and time. It incorporates recommendations for patient-centric care pathway plans from the Institute of Medicine, Medicare’s Oncology Care Model and National Comprehensive Cancer Network guidelines, which include multi-modality planning from diagnosis to survivorship that specifies the clinical team, identification of therapy, and adverse effects and supportive care.

“The 4R model provides a roadmap for the patient and also for the patient’s care team,” said Janeen Bazan, RN, OCN, BSN, lead author of the poster and an oncology nurse navigator from Advocate Sherman Hospital, during the presentation. “It’s very helpful in time management for the patient.”

To understand how the 4R Care Sequence® plans impacted care, investigators surveyed 77 patients with stage 0 to 3 breast cancer from September 2019 to August 2020 at Advocate Sherman Hospital. Of the patients, 28 received 4R Care Sequences® and 49 received a baseline control model.

A survey given to all patients asked whether or not the patients’ care provider instructed them to do certain activities. The investigators found that all patients who received the 4R Care Sequences® were more likely to have been counseled in 8 areas:

  • Getting an immunization (flu, pneumonia, shingles) before starting cancer treatment (52% of baseline cohort, 70% of 4R cohort)
  • Seeing a dentist before starting cancer treatment (13% of baseline cohort, 33% of 4R cohort)
  • Getting a genetic counseling appointment before surgical decision (39% of baseline cohort, 44% of 4R cohort)
  • Managing weight if over or under weight (16% of baseline cohort, 26% of 4R cohort)
  • Getting a nutritionist consult about how to eat during cancer treatment (15% of baseline cohort, 26% of 4R cohort)
  • Getting emotional support (46% of baseline cohort, 52% of 4R cohort)
  • Keeping up appointments with primary care for routine care (67% of baseline cohort, 75% of 4R cohort)
  • Caring for a chronic disease (43% of baseline cohort, 46% of 4R cohort)

Early results showed that the use of the 4R Care Sequences® improved the referrals of recommended breast cancer care. Due to the small sample size, Bazan reported that the results are not statistically significant, however, the trend is still encouraging. The researchers’ plan to continue using 4R Care Sequences, collecting patient surveys and assessing their impact.

“I’m very excited to look at our next data and share with other programs, and hopefully bring in other cancer types,” Bazan said.

Reference

Bazan J. Early results: Impact of 4R (Right Info / Care / Patient / Time) care sequence plans, provided to patients by oncology nurses, on timing and sequence of guideline recommended care. Presented at: Oncology Nursing Society 46th Annual Congress; April 20, 22, 27, and 29, 2021. ePoster 1567. Accessed May 5, 2021. https://bit.ly/3eXEb0n

Recent Videos
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
Related Content